Navigation Links
Par Pharmaceutical Companies Announces Settlement in Principle Regarding Certain Drug Pricing Lawsuits
Date:4/27/2011

WOODCLIFF LAKE, N.J., April 27, 2011 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) announced today it reached a settlement in principle to resolve claims brought by the pharmacy Ven-A-Care of the Florida Keys, Inc. on behalf of the United States, Texas, and Florida under state and federal law, as well as claims brought by the Attorneys Generals of Alaska, South Carolina, and Kentucky under state law for $154 million (pre-tax).

Together with many other pharmaceutical manufacturers, Par is named as a defendant in numerous civil lawsuits that relate to drug price reporting by such companies. The cases, which are pending in federal and state courts, generally allege that the prices reported by pharmaceutical manufacturers caused government entities to pay inflated reimbursements for drugs under Medicaid or other programs. Par denies the allegations.

Upon execution of definitive settlement documents and certain government and court approvals, the settlement will resolve lawsuits relating to federal contributions to state Medicaid programs in 49 states (excluding Illinois), and claims of Texas, Florida, Alaska, South Carolina and Kentucky relating to their Medicaid programs. The settlement will eliminate the majority of the alleged damages asserted against Par in the various drug pricing litigations and removes all trials that had been scheduled to date.

About Par

Par Pharmaceutical Companies, Inc. is a US-based specialty pharmaceutical company. Through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, it develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals. For press release and other company information, visit www.parpharm.com.

Safe Harbor Statement

Certain
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... ROCHESTER, N.Y. , July 23, 2014 ... VSCP ), a leading provider of clinical trial ... , 48, has been named president and chief executive ... of Directors in August 2013 and has held the ... October 25, 2013. Dr. Charles E. ...
(Date:7/23/2014)... 23, 2014 Research and Markets ... in Consumer Healthcare by Application, Sensor Type & by ... 2020" report to their offering. ... an increasing momentum for consumer healthcare monitoring and sensing ... consumer healthcare will lessen the healthcare cost of the ...
(Date:7/23/2014)... MOUNTAIN VIEW, Calif. , July 23, ... in translational preclinical research, today unveiled their new logo ... the transformation of Surpass, corporate culture to one where ... customers. This press release comes on the heels of ... added to the Silicon Valley Team:  David Craig, a ...
Breaking Medicine Technology:Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 2Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 3Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 4Sensor Market in Consumer Healthcare (Patient Monitoring, Therapeutic, Handheld and Homecare, & Fitness and wellness) - Analysis & Forecast to to 2013 - 2020 2Sensor Market in Consumer Healthcare (Patient Monitoring, Therapeutic, Handheld and Homecare, & Fitness and wellness) - Analysis & Forecast to to 2013 - 2020 3SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 3
... Sept. 30, 2011 Haemonetics Corporation (NYSE: ... quarter of its 2012 fiscal year on October 31, ... hold a webcast to discuss and answer questions about ... 31, 2011. Webcast Link: http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=72118&eventID=4204617 ...
... Sept. 29, 2011 Boston Scientific Corporation (NYSE: ... ( NE ural C ardiac T her A ... a prospective, randomized, international clinical feasibility study designed to assess ... heart failure patients.  The study will evaluate 96 patients with ...
Cached Medicine Technology:Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial 2Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial 3Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial 4
(Date:7/23/2014)... Vancouver, BC (PRWEB) July 23, 2014 ... has recently announced the launch of its custom orthotics ... correcting and eliminating foot abnormalities in order to restore ... the joints and cause less fatigue and pain. In ... and reduced pressure in the foot, resulting in relief ...
(Date:7/23/2014)... latest blog post, Best Drug Rehabilitation , which offers ... a stay in rehab can make a big difference in ... a topic that is quickly becoming among the most important ... The Best Drug Rehabilitation blog post on opiate abuse facts ... why they’re considered “the mother of all Schedule II drugs” ...
(Date:7/23/2014)... Children and teens who lose a parent might face an ... study suggests. People who were children or teens when ... death during the study period than those who had not ... Although the study found an association between a parent,s ... wasn,t designed to prove cause-and-effect. Also, the increased risk ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 The European ... in Europe with analysis and projection of revenue. The ... $812.03 million in 2012 to $1,202.08 million by 2018, ... , Browse through the TOC of the European Vitamins ... analysis provided. This also provides a glimpse of the ...
(Date:7/23/2014)... a distinguished electrical equipment retailer, has recently unveiled its collection ... company has decided to provide big price cuts for all ... for the company’s brand new SMA JACK can get a ... quality SMA JACK from RFcnn.com Provides a great help . ... to help make things much easier for worldwide distributors. It ...
Breaking Medicine News(10 mins):Health News:Custom Orthotics at Burnaby PhysioCare Now Correct Foot Abnormalities 2Health News:Latest Best Drug Rehabilitation Blog Post Focuses on Opiate Abuse Facts 2Health News:Parent's Death May Raise Risk of Early Death for Grown Children, Study Suggests 2Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 5Health News:New Collection of SMA JACK Released by China Electrical Accessory Manufacturer RFcnn 2
... has developed new guidelines for starting and monitoring treatments ... first JIA guidelines endorsed by the ACR, with the ... Created as a guide for health care providers, ... of multiple medications used in the treatment of JIA, ...
... venues and a lack of motivation even if those ... for adolescent boys, according to recently published research from a ... boys, attitudes led by Lorraine Robbins from MSU,s College of ... the decrease in exercise typically seen in this age group. ...
... , WEDNESDAY, March 30 (HealthDay News) -- Longer periods ... larger brain growth in offspring, which explains why human ... say researchers. They also said the findings from ... offer further proof that breast-feeding is good for brain ...
... at diagnosis for chronic myeloid leukemia (CML) is over 60 ... data are available about the long-term outcome for older patients ... CML. Results from a study published today in ... of Hematology , reveal that age does not affect response ...
... reduced the blood pressure of a 76-year-old woman ... total knee replacement surgery for osteoarthritis (OA). While ... the woman,s blood pressure dropped dramatically when she ... the April issue of Arthritis Care & ...
... HealthDay Reporter , TUESDAY, March 29 (HealthDay News) -- While ... New research suggests that some people with the disease apparently ... kidney and heart disease. In a group of ... years, nearly 43 percent remained free of serious eye disease, ...
Cached Medicine News:Health News:New clinical practice guidelines developed for juvenile idiopathic arthritis 2Health News:New clinical practice guidelines developed for juvenile idiopathic arthritis 3Health News:Lack of motivation, equipment main barriers for exercise for boys 2Health News:Longer Breast-Feeding May Be Key to Bigger Brains 2Health News:Study reveals no impact of age on outcome in chronic myeloid leukemia patients treated with imatinib 2Health News:Case study reports singing lowers patient's blood pressure prior to surgery 2Health News: Some Type 1 Diabetics Seem Shielded Against Complications 2Health News: Some Type 1 Diabetics Seem Shielded Against Complications 3Health News: Some Type 1 Diabetics Seem Shielded Against Complications 4
... seats and large backrests with lumbar support ... and casters and glides. • Choose the ... variety of environments including: industry, education, laboratory, ... office. • With cast aluminum base • ...
... concave seats and large backrests with ... seats, backrests, armrests, and casters and ... for top performance in a variety ... clean room, static control, health care ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
... seats and large backrests with lumbar support ... and casters and glides. • Choose the ... variety of environments including: industry, education, laboratory, ... office. • With cast aluminum base • ...
Medicine Products: